BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mcdonald T, Liang HA, Sanoja R, Gotter AL, Kuduk SD, Coleman PJ, Smith KM, Winrow CJ, Renger JJ. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. Journal of Neurogenetics 2016;30:32-41. [DOI: 10.3109/01677063.2016.1171862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Li SB, de Lecea L. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology 2020;167:107993. [PMID: 32135427 DOI: 10.1016/j.neuropharm.2020.107993] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
2 Sunagawa M, Takayama Y, Kato M, Tanaka M, Fukuoka S, Okumo T, Tsukada M, Yamaguchi K. Kampo Formulae for the Treatment of Neuropathic Pain ∼ Especially the Mechanism of Action of Yokukansan ∼. Front Mol Neurosci 2021;14:705023. [PMID: 34970116 DOI: 10.3389/fnmol.2021.705023] [Reference Citation Analysis]
3 Joseph Herring W, Ge JY, Jackson S, Assaid C, Connor KM, Michelson D. Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant. Clin J Pain 2018;34:37-43. [PMID: 28448426 DOI: 10.1097/AJP.0000000000000503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]